Amicus Therapeutics, Inc. (NASDAQ:FOLD) Rating Changes as of May 17, 2018

May 17, 2018 - By Jenna Rose

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.21. That’s change of 1.12, from 2017Q3’s 2.33. 25 investors sold all, 48 reduced holdings as Amicus Therapeutics, Inc. ratio dived. 63 increased holdings while 25 funds took holdings. Funds hold 197.59 million shares thus 2.54% more from 2017Q3’s 192.70 million shares.
48,848 are owned by Prelude Capital Llc. Art Advsr Limited Liability Co holds 0.03% or 44,000 shs in its capital. Legal And General Gp Public Ltd Liability stated it has 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Numeric Invsts Ltd Co has 192,431 shs. Amer Century Cos invested in 0% or 100,207 shs. Omega Advsrs reported 100,000 shs stake. Geode Management Lc invested in 1.57M shs or 0.01% of the stock. Cornerstone Capital Management Holding Llc holds 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 69,032 shs. Farallon Cap Management Limited Liability Company invested 0.33% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Hanseatic Management Inc holds 0% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 60 shs. Virginia-based Thompson Davis Co has invested 0.1% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Highland Capital Mgmt Ltd Partnership stated it has 0.19% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Credit Suisse Ag has invested 0.01% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Wellington Management Grp Incorporated Ltd Liability Partnership has invested 0.02% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Manufacturers Life Insurance The holds 0% or 127,025 shs.

Amicus Therapeutics, Inc. registered $3.87 million net activity with 3 buys and 18 insider sales since December 11, 2017. On Monday, December 11 Crowley John F sold $164,973 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD). On Tuesday, January 23 20,000 shs were sold by Barth Jay, worth $336,000. On Tuesday, April 17 $750,000 worth of stock was sold by Do Hung. 32,500 shs valued at $517,371 were sold by Campbell Bradley L on Monday, January 22. On Monday, April 2 Shares for $142,648 were sold by Baird William D III. On Monday, April 2 $71,343 worth of stock was sold by Andrews Kurt J..

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Total analysts of 2 have positions in Amicus Therapeutics (NASDAQ:FOLD) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 8, 2018 according to StockzIntelligence Inc Amicus Therapeutics has 2 analyst reports. On Wednesday, February 7 the rating was maintained by Robert W. Baird with “Buy”. On Thursday, February 8 the rating was maintained by Leerink Swann with “Outperform”. Listed here are Amicus Therapeutics, Inc. (NASDAQ:FOLD) PTs and latest ratings.

07/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $20.0 Maintain
08/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $20 New Target: $24 Maintain

Ticker’s shares touched $16.06 during the last trading session after 9.18% change.Amicus Therapeutics, Inc. is uptrending after having risen 90.40% since May 17, 2017. FOLD has 3.20M volume or 19.83% up from normal. FOLD outperformed the S&P500 by 78.85%.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases.The firm is valued at $3.03 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies.Last it reported negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.